FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses
Jul 30, 2019
Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.
ZEUS Scientific announces U.S. FDA 510(k) clearance of its ZEUS Borrelia Modified Two-Tiered Testing™ (MTTT) algorithm, a paradigm shift in laboratory testing for Lyme disease
Jul 29, 2019
ZEUS Borrelia MTTT™ algorithm has been shown to significantly improve the detection of early Lyme disease with increased sensitivity over the current standard two-tiered testing (STTT) algorithm.
ZEUS Scientific to offer its ZEUS IFA™ product line directly to customers in the United States
Dec 10, 2018
ZEUS Scientific has announced that as of January 1st, 2019, ZEUS will assume all sales, marketing and support functions for all ZEUS IFA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.
Dynex® Technologies announces global partnership with ZEUS Scientific
Jul 27, 2018
Dynex Technologies has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ) enabling ZEUS to sell Dynex instruments to the global clinical market. This new direct partnership builds on the long standing relationship between both companies with Dynex Technologies’ industry proven DS2®, DSX® and Agility® automated ELISA instrumentation and ZEUS Scientific’s broad range of ZEUS ELISA™ Test Systems which use common reagents and universal protocols across a diverse autoimmune and infectious disease menu.
ZEUS Scientific to offer its ZEUS ELISA™ product lines directly to customers in the United States
Dec 20, 2017
ZEUS Scientific has announced that as of February 1st, 2018, ZEUS will assume all sales, marketing and support functions for all ZEUS ELISA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.
ZEUS Scientific announces U.S. FDA Premarket Approvals (PMA) and launch of its ZEUS ELISA™ Parvovirus B19 Test Systems
Sep 21, 2017
ZEUS Scientific announces the launch of ZEUS ELISA Parvovirus B19 IgG and IgM Test Systems, following receipt of Premarket Approvals (PMA) from the U.S. Food and Drug Administration (USFDA). ZEUS ELISA Parvovirus B19 Test Systems are the latest addition to the company’s market leading range of infectious disease diagnostic solutions with seamless integration into the ZEUS ELISA menu of Test Systems. These test systems feature universal reagents and protocol, assay protocol with more flexible incubation times than any other currently available ELISA method, and quick adoption into the lab due to minimal training, enabling in-house testing.
ZEUS Scientific Assumes All Support Functions for AtheNA Multi-Lyte Test Systems
Jul 19, 2016
As of June 14th, 2016, ZEUS Scientific has assumed all the sales, marketing and support functions for all of the AtheNA Multi-Lyte test systems, instruments and consumables for our customers based in the United States. Contact ZEUS directly to find out more about how these multiplex, fluorescent, bead-based assays offer a simple and efficient testing alternative. Be sure that no well is missed with SAVe Diluent(TM), and discover how our proprietary Intra-Well Calibration Technology(R) reduces the number of non-reportable wells in every run to maximize your value in choosing this unique platform!
AMA Adds New CPT Code for SPLA2-IIA Measurement for Cardiovascular Risk Assessment
Jul 23, 2015
ZEUS Scientific has been notified by the American Medical Association (AMA) that the Current Procedural Terminology (CPT) Editorial Panel has accepted its request to add code 0423T to report a test for measurement of secretory type II phospholipase A2 (sPLA2-IIA) protein for assessment of level of risk for cardiovascular event. The code has been posted to the AMA CPT website with an effective implementation date of January 1, 2016.
ZEUS Scientific Expands Cardiology Product Menu With Updated Agreement With Gamma Therapeutics
Jun 4, 2015
ZEUS Scientific and Gamma Therapeutics announced today that they have signed a new agreement providing ZEUS exclusive, worldwide rights to distribute, market and sell the GammaCoeur CVD Risk ELISA test.
ZEUS Scientific Expands ELISA Product Menu With Acquisition of Hama Detection Laboratory Tests
May 26, 2015
ZEUS Scientific announced today that it has finalized an agreement to purchase all right, title, and interest in the ImmuSTRIP HAMA IgG and ImmuSTRIP® HAMA Fragment ELISA kits from Immunomedics, Inc. (NASDAQ: IMMU).
ZEUS Scientific Appoints Corporate Counsel
Jul 24, 2013
ZEUS Scientific, a leading in vitro diagnostic solution provider, is pleased to announce the appointment of Wilentz, Goldman & Spitzer P.A. as its corporate counsel.